Study guide

8.3 Molecular Mechanisms of Target Organ Toxicity: Hepatotoxicity, Nephrotoxicity & Neurotoxicity

DABT: Diplomate of the American Board of Toxicology Exam

Track your progress as you read

Finished sections get a check mark.

1 Exam Overview & Study Design Fundamentals

1.1 Current DABT Exam Facts 1.2 Study Objectives, Hypothesis Testing & Regulatory Guideline Selection 1.3 Test System Selection, Species Models & Animal Welfare (3Rs, IACUC) 1.4 Route Selection, Dosing Regimens & Treatment Duration

2 Dose Selection, Controls & Biostatistics in Toxicology

2.1 Dose Selection Strategies: Range-Finding, Maximum Tolerated Dose (MTD) & Limit Doses 2.2 Control Groups (Negative, Vehicle, Positive, Sham) & Confounding Factors 2.3 Statistical Design, Power Analysis & Statistical Testing of Toxicological Data

3 Study Execution, GLP Compliance & Quality Assurance

3.1 Good Laboratory Practice (GLP) Regulations (FDA 21 CFR Part 58, OECD GLP) & Study Director Responsibilities 3.2 Test Article Characterization, Formulation Analysis, Stability & Homogeneity 3.3 Standard Operating Procedures (SOPs), Quality Assurance Unit (QAU) & Audit Inspections

4 Executing In Vivo, In Vitro, In Silico & Field Studies

4.1 In-Life Clinical Signs, FOB, Body Weight, Food/Water, Ophthalmology 4.2 In Vitro, In Silico (QSAR, Read-Across, PBPK, AI/ML), Field, Clinical & Epidemiologic Characterization

5 Clinical Pathology & Toxicologic Pathology

5.1 Hematology & Coagulation Parameters in Safety Evaluation 5.2 Clinical Chemistry: Biomarkers of Hepatic, Renal & Muscle Injury 5.3 Urinalysis & Specialized Biomarkers of Organ Toxicity 5.4 Toxicologic Pathology: Organ Weights, Gross Necropsy & Histopathology Interpretation

6 Specialized Toxicological Study Endpoints

6.1 Genetic Toxicology Assays: Ames Test, Chromosomal Aberrations & Micronucleus Assays 6.2 Reproductive & Developmental Toxicity Testing (ICH S5, Segments I, II, III) 6.3 Carcinogenicity Bioassays: Design, Conduct & Neoplastic Lesion Evaluation 6.4 Safety Pharmacology (Core Battery: Cardiovascular/hERG, CNS, Respiratory) & Immunotoxicology

7 Toxicokinetics & Biotransformation

7.1 Absorption & Physiological Barriers (Membrane Transport, Blood-Brain Barrier, GI Absorption) 7.2 Distribution, Plasma Protein Binding & Transporters (P-gp, OATs, OCTs, BSEP) 7.3 Phase I Biotransformation: Cytochrome P450 Monooxygenases & Non-CYP Oxidation 7.4 Phase II Biotransformation: Conjugation Pathways, Bioactivation & Detoxification

8 Cellular Mechanisms of Toxicity & Organ Pathogenesis

8.1 Oxidative Stress, Reactive Oxygen/Nitrogen Species (ROS/RNS) & Antioxidant Defenses 8.2 Cell Death Pathways: Necrosis, Apoptosis, Autophagy & Mitochondrial Dysfunction 8.3 Molecular Mechanisms of Target Organ Toxicity: Hepatotoxicity, Nephrotoxicity & Neurotoxicity

9 Hazard Identification & Evidence Integration

9.1 Hazard Identification Principles, Weight of Evidence (WoE) & Systematic Review 9.2 Carcinogen Hazard Classification Schemes (IARC, EPA Guidelines, GHS) 9.3 Agent Classes & Organ-System Toxic Responses

10 Mode of Action, AOPs & Non-Cancer Endpoints

10.1 Mode of Action (MoA) Framework & Human Relevance Evaluation 10.2 Adverse Outcome Pathways (AOP): Molecular Initiating Events, Key Events & Organ-Level Outcomes 10.3 Non-Cancer Systemic Toxicity Endpoints & Target Organ Critical Effects

11 Exposure Assessment Methodologies & Quantification

11.1 Exposure Routes, Scenarios & Pathways (Occupational, Dietary, Environmental, Consumer) 11.2 Exposure Quantification: Dose Equations, Average Daily Dose (ADD) & Lifetime Average Daily Dose (LADD) 11.3 Inhalation Dosimetry: Human Equivalent Concentrations (HEC) & Regional Gas Dose Ratios (RGDR) 11.4 Biomonitoring, Internal Dose, Fate/Transport & BCF

12 Quantitative Dose-Response Principles & Point of Departure Derivation

12.1 Dose-Response Relationships: Threshold vs Non-Threshold, Linear vs Non-Linear Models 12.2 Point of Departure (PoD) Determination: NOAEL, LOAEL & Benchmark Dose (BMD/BMDL) Modeling 12.3 Low-Dose Extrapolation, Cancer Slope Factors (CSF), Unit Risk & First-in-Human Dose

13 Health-Based Guidance Value Derivation & Uncertainty Factors

13.1 Uncertainty Factors (UFs), Interspecies/Intraspecies Extrapolation & Chemical-Specific Adjustment Factors (CSAF) 13.2 Derivation of Reference Values: RfD, RfC, ADI, TDI & Permissible Daily Exposure (PDE)

14 Risk Characterization for Non-Cancer & Cancer Health Effects

14.1 Non-Cancer Risk Characterization: Hazard Quotient (HQ), Hazard Index (HI) & Margin of Exposure (MoE) 14.2 Cancer Risk Characterization: Excess Lifetime Cancer Risk & Acceptable Risk Tolerances 14.3 Uncertainty & Sensitivity Analysis in Risk Characterization

15 Risk Management, Occupational Exposure Limits & Environmental Standards

15.1 Occupational Exposure Limit (OEL) Derivation: OSHA PELs, ACGIH TLVs & NIOSH RELs 15.2 Environmental Quality Standards: Drinking Water MCLs & Air Quality Standards (NAAQS) 15.3 Risk Management Decision-Making, Risk Communication & Socioeconomic Considerations

16 Regulatory Frameworks & Product Stewardship

16.1 Food, Drug & Cosmetic Regulation: FDA Framework, Delaney Clause & GRAS Evaluations 16.2 Chemical Substances & Environmental Regulation: EPA TSCA, FIFRA, Clean Air & Clean Water Acts 16.3 International Regulatory Harmonization: OECD, ICH Guidelines & EU REACH

17 Clinical Toxicology & Medical Management of Poisoning

17.1 Clinical Toxidromes & Initial Management of Acute Poisoning 17.2 Specific Antidotes, Mechanisms of Action & Decontamination Strategies

18 Environmental, Ecological & Public Health Toxicology

18.1 Environmental Toxicology: Fate, Transport, Bioaccumulation (log Kow, BCF) & Ecotoxicological Testing 18.2 Public Health Events, Epidemiology, Susceptible Subpopulations & Exposure Investigation

8.3 Molecular Mechanisms of Target Organ Toxicity: Hepatotoxicity, Nephrotoxicity & Neurotoxicity

Key Takeaways Explain This Topic AI

CYP2E1-rich, relatively hypoxic centrilobular zone 3 explains many bioactivation hepatotoxicants; BSEP/ABCB11 inhibition is a bile-salt cholestatic mechanism distinct from zonal necrosis.

Proximal-tubule organic anion and cation transporters concentrate many nephrotoxicants; male-rat α2u-globulin hyaline-droplet nephropathy has limited human relevance.

Neurotoxicity is classified first as myelin, axon, or neurotransmitter; strychnine is a glycine-receptor antagonist that removes spinal inhibition.

Systems toxicology (II.6) translates a molecular initiating event to cellular, organ, and organism key events; omics without function is not an adverse outcome.

rasH2, p53-heterozygous, and obese or diabetic models have defined strengths and human-disease gaps (II.8); mixture terms are additivity, synergism, potentiation, and antagonism (II.7 C); mechanism plus exposure informs regulation of endocrine disruptors, PBTs, nanoparticles, and tobacco or nicotine (II.7 A).

Last updated: September 2026

From a molecular interaction to an organ and a decision

Handbook II.6 asks you to translate results across sub-cellular, cellular, tissue, individual, species, and population levels using systems toxicology. II.7 asks you to apply mechanistic results to outcomes, prevention, and risk, including endocrine disruptors, microbeads, tobacco/nicotine, persistent bioaccumulative toxins (PBTs), and nanoparticles , and to name mixture interactions. II.8 asks you to use disease and genetically engineered models without confusing them with human disease. Independent ExamFinch material in this section works three classic target organs— liver, kidney, and nervous system —then practices that translation. Full adverse outcome pathway (AOP) formalisms (weight of evidence, essentiality, quantitative key-event relationships) belong in chapter 10. Here you need the mechanism-translation sketch : molecular initiating event → cellular key event → organ key event → organism adverse outcome.

This section is not an ABT product and does not claim official approval, review, or partnership with ABT.

Hepatotoxicity: zonation and bile-salt transporters

The hepatic acinus is oxygen- and enzyme-zoned. Zone 3 (centrilobular) hepatocytes are relatively hypoxic, CYP2E1 - and many CYP3A-rich, and lower in GSH than periportal zone 1 . That is why carbon tetrachloride, chloroform, and acetaminophen (NAPQI after CYP2E1/CYP3A/CYP1A2) produce centrilobular necrosis rather than a random hepatitis. Low zone-3 oxygen tension also favors the reductive dehalogenation of CCl4 taught in section 8.1. Zone 1 injury (allyl alcohol; some iron-overload patterns) is the contrast case: oxygen-rich, GSH-rich, different enzymes.

Cholestatic injury is often a transporter story, not a CYP-zonation story. The canalicular bile salt export pump (BSEP, ABCB11) is the ATP-dependent efflux pump for taurine- and glycine-conjugated bile acids. Human genetic BSEP failure ( PFIC2 ) shows what intracellular bile-salt detergent does to hepatocytes when the pump is missing—physiology that II.1 D wants you to connect to drug inhibition. Chemicals that inhibit or down-regulate BSEP (troglitazone, bosentan, some cyclosporine exposures) let bile salts accumulate. The clinicopathologic face is cholestasis with ALP, GGT, and bilirubin more than a pure ALT leak. MRP2 (ABCC2) and NTCP (SLC10A1) complete the uptake/efflux set; a chemical can inhibit BSEP and also block compensatory basolateral efflux, worsening the intracellular load. Do not call every high ALP “zone-3 ROS.”

Nephrotoxicity: proximal-tubule transporters and α2u-globulin

The proximal tubule (S1–S3) reabsorbs the filtered load and runs organic anion transporters (OAT1/SLC22A6, OAT3/SLC22A8) on the basolateral membrane plus apical efflux. Those transporters concentrate β-lactam antibiotics, many antivirals, ochratoxin A, and conjugated metabolites inside the tubule cell—an uptake molecular initiating event, not a slogan that “the kidney is sensitive.” Organic cation transporter 2 (OCT2) similarly concentrates cisplatin ; cimetidine can compete at OCT2. Injury markers and outer-stripe (S3) preference follow blood flow, hypoxia, and that transporter map.

α2u-globulin nephropathy is the human-relevance trap. Adult male rats synthesize a large amount of hepatic α2u-globulin under androgen control. Some hydrocarbons and their metabolites ( d-limonene 1,2-oxide, 2,2,4-trimethylpentane metabolites, decalin, isophorone) bind that protein. The complex resists lysosomal degradation, appears as hyaline droplets in proximal tubules, and can drive cytotoxicity, regeneration, and, in chronic studies, a male-rat renal-tumor promotion pathway. Female rats, male mice, and humans do not run this androgen-driven protein load. Humans have related lipocalins at much lower abundance; they do not reproduce the syndrome. For this mode of action, human relevance is limited . Do not promote a male-rat hyaline-droplet chemical to a default human renal carcinogen on α2u evidence alone, and do not ignore a second mechanism the same molecule might have.

Neurotoxicity: myelin, axon, and neurotransmitter

Classify nervous-system injury by the structure first .

Myelin / Schwann cell or oligodendrocyte. Vacuolation, stripping, slowed conduction. Teaching examples include hexachlorophene-type white-matter edema and tellurium-induced peripheral myelin injury. The cell that fails first is the myelinating cell, not the axon cylinder.

Axon (axonopathy). Distal dying-back after cytoskeletal or energy failure. Acrylamide is a standard distal axonopathy example. Some organophosphate delayed neuropathies travel through neuropathy target esterase aging rather than through acute acetylcholinesterase crisis. The soma may look intact early.

Neurotransmitter / receptor. Too much or too little synaptic inhibition or excitation without a requirement for structural myelin loss. Strychnine is a competitive glycine-receptor antagonist (section 8.2): loss of spinal inhibition, tetanic convulsions, individual death from respiratory failure. Organophosphate acetylcholinesterase inhibition is a different transmitter story (acetylcholine excess). Tetrodotoxin is a voltage-gated sodium-channel pore block—still channel-level, not myelin. Mixing these three is how every tremor becomes undifferentiated “neurotoxicity.”

Systems toxicology: translating across levels (II.6)

II.6 A–B are the craft of moving a result from a simple system to a more complex one without pretending they are equal. A mitochondrial ROS assay is a sub-cellular observation. A hepatocyte GSH drop is cellular . Centrilobular necrosis is tissue/organ . Jaundice and death are individual . A mouse-to-human CYP2E1 difference is species . A change in liver-related mortality in an exposed town is population . Each step needs a method: enzyme kinetics, histology, PBPK, epidemiology—not a leap.

II.6 C reminds you that anatomical and biochemical differences change magnitude : a male-rat α2u load, a dog’s corticosteroid ALP isoform, a human cardiomyocyte’s low catalase. II.6 D is honesty about computational network tools: they organize omics and suggest nodes; they do not replace an apical adverse outcome. II.6 E again: omics relate to organism effects only through those key events. The four-box sketch below is the translation you should be able to fill with named biology for a bioactivated solvent. Chapter 10 will add Bradford Hill-style essentiality and quantitative key-event relationships.

Disease and genetically engineered models (II.8)

rasH2 (c-Ha-ras transgenic mouse) is a 26-week alternative carcinogenicity model used in ICH S1B weight-of-evidence packages. It can detect many genotoxic and some nongenotoxic rodent carcinogens faster than a two-year mouse study. It is not a miniature human carcinoma. Ras-pathway bias and mouse background tumors are limitations ( II.8 B ).

p53+/− (heterozygous Trp53) 26-week assays are generally more sensitive to genotoxic carcinogens that benefit from reduced p53 dosage. They can miss some receptor-mediated, nongenotoxic rodent carcinogens that need a full lifetime and an intact tumor-suppressor context. A negative p53+/− study is not “not a human carcinogen.”

Obese and diabetic models (ob/ob, db/db, Zucker diabetic fatty, diet-induced obesity) increase hepatic fat, alter CYP expression, and can unmask drug-induced liver injury that a lean Wistar would miss. The leptin-mutation models are not polygenic human type 2 diabetes. Use them to test a mechanistic hypothesis about steatosis or insulin resistance as a susceptibility factor (II.3 disease-state), and state the gap.

II.8 A also covers building an alternative model from a mechanism (a humanized CYP2E1 mouse after you already know CYP2E1 is the initiating enzyme). That is the opposite of hoping a random disease model will reveal the mode of action.

Mixtures: additivity, synergism, potentiation, antagonism (II.7 C)

Additivity means the combined effect equals the sum predicted by dose addition (similar mode of action; concentration addition) or response addition (independent modes). Naming which null model you used is the skill.

Synergism means the combined effect is greater than that additive prediction, and both agents can be toxic on their own.

Potentiation means chemical A is not toxic alone at the dose used but increases the toxicity of B. Classic teaching: isopropanol potentiates carbon tetrachloride hepatotoxicity. Ethanol induction of CYP2E1 increasing CCl4 injury is a related susceptibility phenotype that often gets discussed in the same breath.

Antagonism means the combined effect is less than additive. Functional (opposing physiology), chemical (chelation), dispositional (induced clearance), or receptor (a blocker) are the usual subtypes.

Do not call every “worse than I expected” synergism until you have stated the additive null.

Applying mode of action to regulation, conceptually (II.7 A)

You are not asked to recite every statute. You are asked how mechanism plus exposure changes a control decision.

Endocrine disruptors. An estrogen-receptor, androgen-receptor, or thyroid-pathway initiating event is why receptor-binding and steroidogenesis screens exist and why some uses are restricted even when apical cancer bioassays are messy.

PBTs. Persistence, bioaccumulation, and toxicity drive listing (Stockholm Convention; TSCA PBT). The T is a mode-of-action problem (AhR for some dioxin-like compounds; neuronal calcium and mitochondria for methylmercury). P and B are fate problems; a beautiful cellular mechanism does not make a chemical less persistent.

Nanoparticles. Primary particles, agglomerates, dissolution (ion release versus particle), surface reactivity, and frustrated phagocytosis ROS in macrophages are the mechanistic vocabulary. Regulation (TSCA; REACH nano provisions) still treats many nanoforms as poorly predicted by the dissolved ion alone.

Tobacco / nicotine. Nicotine’s nicotinic acetylcholine receptor pharmacology explains addiction and some cardiovascular effects; nitrosamines and PAHs explain much of the cancer chemistry. Product regulation uses both exposure reduction and mechanistic toxicology.

Microbeads. The handbook lists them with these products. The dominant problem is physical persistence and sorption of other chemicals in aquatic systems—an exposure and fate control (bans on rinse-off microbeads)—not a CYP2E1 story.

II.7 B and II.7 D close the loop: in vitro and in vivo mechanistic data populate the translation sketch, and cellular and biochemical mechanisms are how you evaluate risk to humans, animals, and the environment—without claiming a binding assay is already a population adverse outcome.

Organ or decision Initiating event or uptake Cellular key event Organ key event Human-relevance note

Zone-3 hepatocyte CYP2E1 bioactivation and ROS Lipid peroxidation and MPT Centrilobular necrosis, ALT leak Depends on human CYP2E1 and GSH

Cholestasis BSEP inhibition Bile-salt retention, mitochondrial injury Cholestatic chemistry, biliary reaction Transporter homology is good; kinetics differ

Proximal tubule OAT or OCT concentrative uptake ATP failure, cell death Acute tubular injury Human OATs exist; substrate-specific

Male-rat hyaline droplets α2u-globulin binding Lysosomal overload Tubular injury; possible male-rat tumors Limited human relevance for this mode of action

Myelin vs axon vs synapse Cell-specific target Demyelination, dying-back, or receptor block Neuropathy or acute convulsant death Map the structure before the statute

rasH2 or p53+/− Engineered pathway bias Altered tumor latency 26-week tumor call Strength for screening; not human identity

Mixture potentiation A changes B’s activation or defense More of B’s cellular key event More organ injury from B State the additive null first

Scenario

A hydrocarbon produces male-rat hyaline droplets, no female-rat renal tumors, and no human-protein binding analog. The cautious reading for that mode of action is limited human renal-tumor relevance. The same dossier must still ask whether the chemical is also a PBT, an endocrine-active substance, or a nanoparticle surface catalyst—those are separate II.7 questions.

A second file: a nanoparticle plus endotoxin contamination produces a greater-than-additive macrophage IL-1β response, and both materials can activate innate immunity alone. That is synergism . Isopropanol plus a CCl4 dose that is not hepatotoxic alone becomes necrotic: potentiation . A computational network that lights an Nrf2 node without necrosis or dysfunction remains a hypothesis , not an organism adverse outcome.

Traps

Treating α2u-globulin male-rat tumors as default human renal carcinogens.

Calling BSEP cholestasis “centrilobular CYP2E1 necrosis.”

Using rasH2 or p53+/− as interchangeable with human cancer or with each other.

Skipping the additive model before calling synergism.

Equating an omics node or a receptor screen with an organism or population adverse outcome.

Treating a microbead ban as if it were a Fenton-chemistry decision.

Loading diagram... Mechanism translation sketch: MIE to organism adverse outcome